Switch theme
Sign up to access all valuation multiples
China Medical System Holdings Ltd is active in the healthcare segment. It is one of the China-based pharmaceutical services companies in the country. The company's business mainly involves the marketing, promotion, and sales of prescription pharmaceutical products manufactured by domestic pharmaceutical companies. Some of its products include Plendil, Salofalk, Combizym, and others.
2006
4.7K+
LTM Revenue $1.2B
LTM EBITDA $292M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
China Medical System has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $292M.
In the most recent fiscal year, China Medical System achieved revenue of $951M and an EBITDA of $294M.
China Medical System expects next 12-month revenue of XXX and NTM EBITDA of XXX
See China Medical System valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $951M | XXX | XXX | XXX |
| Gross Profit | $866M | XXX | $691M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $292M | XXX | $294M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 31% | XXX | XXX | XXX |
| EBIT | $266M | XXX | $221M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $248M | XXX | $206M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, China Medical System's stock price is HKD 12 (or $2).
China Medical System has current market cap of HKD 29.3B (or $3.7B), and EV of HKD 23.8B (or $3.0B).
See China Medical System trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.7B | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, China Medical System has market cap of $3.7B and EV of $3.0B.
China Medical System's trades at 3.2x EV/Revenue multiple, and 10.3x EV/EBITDA.
Equity research analysts estimate China Medical System's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
China Medical System has a P/E ratio of 16.5x.
See valuation multiples for China Medical System and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBIT | 12.5x | XXX | 13.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 16.5x | XXX | 18.1x | XXX | XXX | XXX |
| EV/FCF | 17.1x | XXX | 29.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChina Medical System's last 12 month revenue growth is 14%
China Medical System's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
China Medical System's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
China Medical System's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for China Medical System and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | -18% | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
China Medical System acquired XXX companies to date.
Last acquisition by China Medical System was XXXXXXXX, XXXXX XXXXX XXXXXX . China Medical System acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was China Medical System founded? | China Medical System was founded in 2006. |
| Where is China Medical System headquartered? | China Medical System is headquartered in Hong Kong. |
| How many employees does China Medical System have? | As of today, China Medical System has 4.7K+ employees. |
| Is China Medical System publicy listed? | Yes, China Medical System is a public company listed on HKG. |
| What is the stock symbol of China Medical System? | China Medical System trades under 00867 ticker. |
| When did China Medical System go public? | China Medical System went public in 2010. |
| Who are competitors of China Medical System? | Similar companies to China Medical System include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of China Medical System? | China Medical System's current market cap is $3.7B |
| What is the current revenue of China Medical System? | China Medical System's last 12 months revenue is $1.2B. |
| What is the current revenue growth of China Medical System? | China Medical System revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of China Medical System? | Current revenue multiple of China Medical System is 2.8x. |
| Is China Medical System profitable? | Yes, China Medical System is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of China Medical System? | China Medical System's last 12 months EBITDA is $292M. |
| What is China Medical System's EBITDA margin? | China Medical System's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of China Medical System? | Current EBITDA multiple of China Medical System is 11.4x. |
| What is the current FCF of China Medical System? | China Medical System's last 12 months FCF is $194M. |
| What is China Medical System's FCF margin? | China Medical System's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of China Medical System? | Current FCF multiple of China Medical System is 17.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
